This site is intended for healthcare professionals
Abstract digital waveforms in blue and purple
  • Home
  • /
  • Drugs
  • /
  • S
  • /
  • Sumatriptan
  • /
  • Sumatriptan SUMATRIPTAN SUCCINATE 100 mg/1 NuCare Pharmaceuticals,Inc.
FDA Drug information

Sumatriptan

Read time: 1 mins
Marketing start date: 26 Jan 2025

Summary of product characteristics


Effective Time

20240619

Version

3

Spl Product Data Elements

Sumatriptan Sumatriptan Succinate CROSCARMELLOSE SODIUM CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS MAGNESIUM STEARATE MICROCRYSTALLINE CELLULOSE POLYSORBATE 80 SODIUM BICARBONATE SUMATRIPTAN SUCCINATE SUMATRIPTAN White to off-white biconvex C;34

Application Number

ANDA078327

Brand Name

Sumatriptan

Generic Name

Sumatriptan Succinate

Product Ndc

68071-5072

Product Type

HUMAN PRESCRIPTION DRUG

Route

ORAL

Package Label Principal Display Panel

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - pdp

Spl Medguide

Sumatriptan Succinate Tablets

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Disclaimer

The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).

Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.

Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.